Tissue Inhibitor of Metalloproteinases
"Tissue Inhibitor of Metalloproteinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of secreted protease inhibitory proteins that regulates the activity of SECRETED MATRIX METALLOENDOPEPTIDASES. They play an important role in modulating the proteolysis of EXTRACELLULAR MATRIX, most notably during tissue remodeling and inflammatory processes.
| Descriptor ID |
D019714
|
| MeSH Number(s) |
D12.776.645.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tissue Inhibitor of Metalloproteinases".
Below are MeSH descriptors whose meaning is more specific than "Tissue Inhibitor of Metalloproteinases".
This graph shows the total number of publications written about "Tissue Inhibitor of Metalloproteinases" by people in this website by year, and whether "Tissue Inhibitor of Metalloproteinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 2 | 4 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tissue Inhibitor of Metalloproteinases" by people in Profiles.
-
Serum Amyloid P Attenuates Hypertrophic Scarring in Large Animal Models. J Surg Res. 2023 10; 290:285-292.
-
CpG postconditioning after reperfused myocardial infarction is associated with modulated inflammation, less apoptosis, and better left ventricular function. Am J Physiol Heart Circ Physiol. 2020 11 01; 319(5):H995-H1007.
-
Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload. J Mol Cell Cardiol. 2018 04; 117:36-48.
-
Hypothesis: Metalloproteinase Inhibitors Decrease Risks of Cardiovascular Disease. J Cardiovasc Pharmacol Ther. 2016 07; 21(4):368-71.
-
Matrix metalloproteinase levels in chronic thoracic aortic dissection. J Surg Res. 2014 Jun 15; 189(2):348-58.
-
Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ Heart Fail. 2012 Jul 01; 5(4):462-6.
-
An update on pharmacological interventions for diabetic foot ulcers. Foot Ankle Spec. 2010 Oct; 3(5):285-302.
-
The role of angiocidin in sarcomas. Cancer. 2009 Nov 15; 115(22):5251-62.
-
Thoracic aortic dissection: are matrix metalloproteinases involved? Vascular. 2009 May-Jun; 17(3):147-57.
-
Expression of matrix metalloproteinases during experimental Candida albicans keratitis. Invest Ophthalmol Vis Sci. 2009 Feb; 50(2):737-42.